Discovering significant breakthroughs in fibrosis.
Blade Clinical Trials
BLD-2660 will next advance into a Phase 2a trial in patients idiopathic pulmonary fibrosis (scheduled to start in Q2 2020). Additionally, a first-in-human trial with BLD-0409 started in January 2020.
Idiopathic Pulmonary Fibrosis
BLD-2660 recently completed a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial, and demonstrated safety and tolerability in healthy participants (ClinicalTrials.gov NCT03559166).
B-2660-203, a Phase 2 trial to be conducted in Idiopathic Pulmonary Fibrosis (IPF) patients, is planned to commence Q2 2020. This is a multi-center, randomized, double-blind, placebo-controlled trial to be conducted in approximately 24 subjects, treated for 28 days duration. These subjects will be assessed for changes in lung calpain activity and a variety of other biomarkers noted to be important in IPF disease activity (Clinicaltrials.gov NCT04244825).
Chronic Liver Disease
Blade’s autotaxin inhibitor, BLD-0409, is now being studied in a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial to assess safety, tolerability and pharmacokinetics in healthy participants (Clinicaltrials.gov NCT04146805).
BLD-0409 is the lead candidate for the Phase 2 trial in Non-Alcoholic Steatohepatitis (NASH), projected to begin Q2 2021.
Another Phase 2 trial will study the effect of BLD-0409 in patients with Primary Biliary Cholangitis (PBC) and moderate to severe pruritus. This trial is projected to commence in Q4 2020.